SCHEMBL16396288

SCHEMBL16396288

O=C(O)Cc1ccccc1NC(=O)c1cc(Cl)cc(Cl)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SUCNR1 Q9BXA5 8/20 0.55
▸ CFD P00746 5/20 0.52
▸ CXCL8 P10145 3/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ NR1H4 Q96RI1 2/20 0.49
▸ F11 P03951 2/20 0.47
▸ CAMK2A Q9UQM7 1/20 0.47
▸ TTR P02766 2/20 0.47
▸ AKR1B10 O60218 1/20 0.47
▸ UGT1A9 O60656 1/20 0.47
▸ TRPA1 O75762 1/20 0.47
▸ ABCB11 O95342 1/20 0.47
▸ MT-CO2 P00403 1/20 0.47
▸ ALB P02768 1/20 0.47
▸ UGT1A6 P19224 1/20 0.47
▸ UGT1A1 P22309 1/20 0.47
▸ PTGS1 P23219 1/20 0.47
▸ CXCR1 P25024 1/20 0.47
▸ ADRA1A P35348 1/20 0.47
▸ PTGS2 P35354 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16410309 0.82 NR1H4 (0.40) SUCNR1CFDCYP2C9NR1H4TTR
SCHEMBL16396279 0.78 CFD (0.80) SUCNR1CFDF11TPSB2
SCHEMBL17802659 0.77 CFD (0.66) SUCNR1CFDF11TPSB2
SCHEMBL23413100 0.77 POLB (0.59) —
SCHEMBL31359276 0.77 POLB (0.59) —
SCHEMBL16397545 0.76 KMT2A (0.65) SUCNR1CFDCXCL8CYP2C9NR1H4
SCHEMBL28513534 0.76 CFD (0.59) SUCNR1CFDCXCL8CYP2C9NR1H4
SCHEMBL16396842 0.75 SUCNR1 (0.60) SUCNR1CFDCXCL8CYP2C9NR1H4
SCHEMBL28516387 0.75 CFD (0.56) SUCNR1CFDCXCL8CYP2C9NR1H4
SCHEMBL21711305 0.74 NR1H4 (0.75) SUCNR1CFDCXCL8CYP2C9NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016088082-A1 AMIDOMETHYL-BIARYL DERIVATIVES COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2016-06-09 — — WO disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 — — EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB SUCNR1 4670/4885CFD 1/4885CXCL8 2227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback